Ethical concerns in the use of palliative drug treatment for Alzheimer's Disease
Abstract
The cases of 3 patients with Alzheimer's disease (AD) who had varied outcomes from treatment with tacrine or other palliative drugs illustrate the need to consider the benefits of such agents for each case on an individual basis. In the absence of a cure, the most important factor in the care of AD patients may be the physician's attitude that irreversibility does not imply untreatability.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
